Compare Phillips 66 (PSX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Sana Biotechnology Inc — how do they compare? Phillips 66 trades at $262.98 (market cap $104.06B), while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: Phillips 66 is far larger — about 109.8× Sana Biotechnology Inc's market cap, and Phillips 66 pays a 1.95% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PSX | SANA | |
|---|---|---|
Market Cap | $104.06B | $947.48M |
Sector | Energy | Health |
52-Week High | $260.78 | $5.92 |
52-Week Low | $126.76 | $2.68 |
Enterprise Value | $120.52B | $860.73M |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $259.14, up 1.59% over 24 hours and near its 52-week high, with bullish technical indicators and strong support at $258. The stock shows robust fundamentals, including a P/E of 14.79 and ROE of 24.02%, while recent quarterly earnings consistently beat expectations. Positive news highlights refining strength amid elevated energy prices, with institutional buying supporting momentum.
Outlook remains favorable due to earnings growth and cost initiatives, but risks include volatile refining margins and debt levels. Analysts are bullish with a $242.45 consensus target, though current price exceeds it, suggesting cautious optimism for further upside if operational targets are met.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
